Yemen Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.

Press releases published on September 30, 2026

20 minutes ago

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

Indeterminate GlobeNewswire

22 minutes ago

Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

Indeterminate GlobeNewswire

22 minutes ago

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Indeterminate GlobeNewswire

22 minutes ago

Project MEND Uses SteraMist to Safely Disinfect Medical Equipment for Reuse

Indeterminate GlobeNewswire

22 minutes ago

Decoy Therapeutics to Present at The Small Cap Showcase

Indeterminate GlobeNewswire

22 minutes ago

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Indeterminate GlobeNewswire

an hour ago

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Indeterminate GlobeNewswire

an hour ago

Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards

Indeterminate GlobeNewswire

an hour ago

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Indeterminate GlobeNewswire

an hour ago

DiFusion Activates Operating Board to Scale Therapeutic Biomaterials Platform

Indeterminate GlobeNewswire

an hour ago

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Indeterminate GlobeNewswire

an hour ago

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

Indeterminate GlobeNewswire

an hour ago

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

Indeterminate GlobeNewswire

an hour ago

Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)

Indeterminate GlobeNewswire

an hour ago

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Indeterminate GlobeNewswire

an hour ago

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Indeterminate GlobeNewswire

an hour ago

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Indeterminate GlobeNewswire

an hour ago

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Indeterminate GlobeNewswire

an hour ago

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire

an hour ago

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Indeterminate GlobeNewswire